Gitelman syndrome (GS) is an autosomal recessive disorder characterized by hypokalemic metabolic alkalosis in conjunction with significant hypomagnesemia and hypocalciuria. The GS phenotype is caused by mutations in the solute carrier family 12, member 3 (SLC12A3) gene that encodes the thiazide-sensitive NaCl cotransporter (NCC). We analyzed DNA samples of 163 patients with a clinical suspicion of GS by direct sequencing of all 26 exons of the SLC12A3 gene. In total, 114 different mutations were identified, 31 of which have not been reported before. These novel variants include 3 deletions, 18 missense, 6 splice site and 4 nonsense mutations. We selected seven missense mutations to investigate their effect on NCC activity and plasma membrane localization by using the Xenopus laevis oocyte expression system. The Thr392Ile mutant did not display transport activity (probably class 2 mutation), while the Asn442Ser and Gln1030Arg NCC mutants showed decreased plasma membrane localization and consequently function, likely due to impaired trafficking (class 3 mutation). Even though the NaCl uptake was hampered for NCC mutants Glu121Asp, Pro751Leu, Ser475Cys and Tyr489His, the transporters reached the plasma membrane (class 4 mutation), suggesting an effect on NCC regulation or ion affinity. The present study shows the identification of 38 novel mutations in the SLC12A3 gene and provides insight into the mechanisms that regulate NCC.
INTRODUCTION
Gitelman syndrome (GS) (OMIM 263800) is an autosomal recessive renal tubular salt wasting disorder, primarily characterized by hypokalemic metabolic alkalosis in combination with significant hypomagnesemia and low urinary calcium. 1 GS is the most frequently occurring renal tubular disorder with a prevalence of 1:40 000 in the Caucasian population (heterozygotes 1:100). 2 The GS phenotype can be observed from the age of 6 years, but in most instances the diagnosis is made during adulthood. 3 Transient periods of muscle weakness and tetany 1,4 sometimes accompanied by abdominal pain, vomiting and fever are often seen in GS patients. Remarkably, some patients are completely asymptomatic except for the appearance of chondrocalcinosis at adult age. 5, 6 A minority of patients with GS have a mutation in the CLCNKB gene, coding for chloride channel subunit b (ClC-Kb). In most cases, GS results from loss-of-function mutations in the solute carrier family 12, member 3 (SLC12A3) gene, which consists of 26 exons and is located on the long arm of chromosome 16 (16q13) . The SLC12A3 gene encodes the 1030 amino-acid thiazide-sensitive NaCl cotransporter (NCC) protein (NM_000339.2; OMIM 600968). 7 The two-dimensional structure of NCC is predicted to contain 12 transmembrane segments (S) with large intracellular amino (N)-and carboxy (C)-terminal regions, and a large hydrophilic extracellular loop between S7 and S8. 8 NCC localizes to the luminal membrane of the DCT segment of the nephron, 9 where it facilitates the cotransport of Na + and Cl À from the pro-urine to the intracellular compartment.
NCC is the target for thiazide-type diuretics, which are currently recommended as the first-line pharmacological treatment of hypertension. 10 Chronic thiazide administration, on the other hand, induces similar electrolyte disturbances as seen in GS. 11 At present, B250 distinct loss-of-function mutations have been discovered in patients with GS (Human Gene Mutation Database, http://biobase-international.com). Most are missense mutations substituting a conserved amino-acid residue, whereas nonsense, frameshift and splice site mutations and gene rearrangements are less frequently observed. These mutations presumably impair the function of the encoded NCC protein as a result of structural changes and/or altered cellular localization. So far, functional analysis has been performed for only a limited number of mutations. [12] [13] [14] [15] To confirm disease-causing NCC mutants, Xenopus laevis oocytes were used as a model system to investigate Na + transport by NCC and cell surface localization. These mutants are categorized according to standard nomenclature as established for renal Na + transporter's NCC and NKCC2 mutations. 16 Here, we report the identification of 31 novel SLC12A3 sequence variants, that are predicted to result in loss of function of the SLC12A3 protein and are considered to be disease-causing mutations. We selected seven missense mutations (five novel mutations and two previously described) to characterize their functional and molecular properties by performing a quantitative analysis comparing wild-type to mutant NCC plasma membrane expression as well as by evaluating their NCC transport activity. The present study expands the spectrum of SLC12A3 mutations and evaluates their effect on NCC function to ultimately elucidate the molecular mechanisms underlying GS.
MATERIALS AND METHODS

Mutation analysis
Patient samples were sent to the DNA diagnostic service of the Department of Human Genetics of our hospital for diagnostic analysis of the SLC12A3 gene. Most samples were sent from nephrology, endocrinology and genetic services in the Netherlands, but samples from other European countries (eg, Belgium, Sweden and Italy) were also tested. We relied on the expertize of the referring medical doctors for inclusion of patients for diagnostic testing, and we did not actively ask for clinical details of patients. However, all patients with a clinical description on the request form (about 75% of cases) fulfilled the classical criteria for GS. DNA was extracted from peripheral blood lymphocytes using standard procedures. All individual exons of the SLC12A3 gene were PCR amplified (primers and PCR conditions available upon request), and direct sequencing was performed on an ABI 3730 automated DNA sequencer (Life Technologies Division Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). The segregation of mutations has been studied in case family members were available. GenBank accession number NM_000339.2 is used as a reference sequence, in which the A of ATG is number 1. Intron sequences can be found in NT_010498.15.
Multiplex ligand-dependent probe amplification
For the multiplex ligation-dependent probe amplification (MLPA) analysis, the SALSA MLPA kit P136 (MRC-Holland, Amsterdam, The Netherlands) was used. This kit contains 25 MLPA probes covering all exons, except exon 6 of the SLC12A3 gene. Furthermore, a home-designed kit was used containing synthetic probes including all coding exons (also exon 6). The analysis and data processing were performed as described by Koolen et al. 17 
DNA constructs
To allow hNCC detection at the plasma membrane of X. laevis oocytes, enhanced green fluorescent protein (eGFP) was introduced at the N-terminus of hNCC. The eGFP-hNCC pT7Ts construct was obtained by replacement of the N-terminal flag-tag of the previously described flag-hNCC pT7Ts construct 12 by the eGFP from the eGFP-hNCC pCB7 construct using Nco1 and Nae1 restriction enzymes (New England Biolabs, Bioke, Leiden, The Netherlands). All selected mutations were introduced into eGFP-hNCC pT7Ts by use of the Quikchange Site-Directed Mutagenesis Kit (Stratagene, Bio-Connect BV, Huissen, The Netherlands), according to the manufacturer's instructions. The primers are depicted in Supplementary Table 2.
In vitro NCC cRNA translation
To prepare cRNA, all clones were linearized using NsiI (New England Biolabs), and cRNA was in vitro transcribed using a T 7 RNA polymerase mMESSAGE machine kit (Ambion, Life Technologies Division Applied Biosystems), according to manufacturer directions. Additionally, all samples were resolved on a 1% w/v formaldehyde agarose gel to evaluate the cRNA quality, while the concentration was determined by absorbance reading at 260 nm using the NANODROP 2000c (Thermo scientific, Breda, The Netherlands). cRNA aliquots were stored at À801C.
X. laevis oocyte preparation
The animal ethics board of the Radboud University Nijmegen Medical Centre approved the animal studies. Microinjection, isolation and 22 Na + tracer uptakes in X. laevis oocytes were performed as described previously, 18 with minor modifications. In brief, oocytes were harvested by postmortem surgery (abdominal laparotomy) after decapitation of adult female X. laevis and incubated in frog Ringer ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl and 5 mM Hepes/Tris, pH 7.4) in the presence of collagenase B (2 mg/ml) for 1 h. The oocytes were washed four times in ND96, defolliculated and incubated overnight at 181C in ND96 supplemented with 2.5 mM sodium pyruvate and 5 mg/100 ml of gentamicin. Next day, mature oocytes were microinjected with 50 ml of water only or containing cRNA (10 ng of cRNA/oocyte). The oocytes were incubated at 181C for 3 days in ND96 with 2.5 mM sodium pyruvate and 5 mg/100 ml gentamicin that was changed every 24 h. The night before the uptake experiments were performed, the oocytes were incubated in Cl À -free ND96 (96 mM Na + -isethionate, 2 mM K + -gluconate, 1.8 mM Ca 2+ -gluconate, 1 mM Mg 2+ -gluconate, 5 mM Hepes, pH 7.4, 2.5 mM sodium pyruvate and 5 mg/100 ml gentamicin).
X. laevis oocyte total membrane isolation
For the isolation of the total membrane fraction, oocytes were homogenized in 20 ml Hba buffer (20 mM TRIS, pH 7.4, 5 mM NaH 2 PO 4 , 1 mM EDTA, 80 mM sucrose, 1 mM PMSF, 1 mg/ml leupeptin and 10 mg/ml pepstatin) per oocyte, and centrifugated twice for 10 min at 100 g at 41C (each time the supernatant was collected). Following membranes were isolated by 20 min centrifugation at 14 000 g. The pellet was resuspended in 2 ml leammli/DTT per oocyte.
Western blotting
eGFP-NCC expression was analyzed by immunoblot analysis for the total plasma membrane fraction. Protein samples were incubated for 10 min at room temperature in leammli buffer, subjected to electrophoresis on a 10% w/v SDS-polyacrylamide gel and immunoblotted onto PVDF membranes (Millipore Corporation, Amsterdam, The Netherlands) according to standard procedures. Membranes were blocked for 1 h in 5% w/v non-fat dried milk in TBS-T (TBS with 0.1% v/v Tween-20). Overnight, blots were incubated with a rabbit polyclonal BFP antibody (1:5000 in 1% w/v milk TBS-T), 19 following 2-h incubation with a PO-conjugated anti-rabbit antibody (1:10 000 in 1% w/v milk TBS-T) (Sigma, Zwijndrecht, The Netherlands, no. A 491). The blots were incubated with SuperSignal West Pico (Thermo scientific) before visualization by chemiluminescence in the chemidoc XRS imager (Biorad, Veenendaal, The Netherlands).
Na + transport assays
Human eGFP-NCC cotransporter function was determined by assessing tracer 22 Na + uptake (PerkinElmer Life Sciences, Groningen, The Netherlands) in groups of 25 oocytes following a standard protocol of 30 min of incubation in a Cl À -free ND96 medium containing 1 mM ouabain, 0.1 mM amiloride and 0.1 mM bumetanide, following 1 h of uptake in K + -free, NaCl medium (40 mM NaCl, 56 mM sodium-gluconate, 4 mM CaCl 2 , 1 mM MgCl 2 and 5 mM Hepes/Tris, pH 7.4) containing 1 mM ouabain, 0.1 mM amiloride, 0.1 mM bumetanide and 2 m Ci of 22 Na + /ml. 20 As a control, one group of waterinjected oocytes has been included to determine the basal unspecific tracer 22 Na + uptake in all experiments.
Immunofluorescence microscopy
Human eGFP-NCC cotransporter X. laevis oocyte membrane localization was assessed in groups of B10 oocytes by use of confocal microscopy. 21 The images were obtained with an Olympus FV1000 Confocal Laser Scanning Microscope (Olympus, Center Valley, PA, USA), emitting at 488 nm with a 30-mW argon laser. The plasma membrane fluorescence was quantified for all images by measuring pixel intensity using ImageJ (Image Processing Program, NIH, USA) software.
Statistical analysis
In all experiments, the data are expressed as mean ± SEM. Overall statistical significance was determined by one-way ANOVA, followed by a Bonferroni post-hoc test. Po0.05 was considered significant.
RESULTS
Screening for SLC12A3 mutations by sequence analysis
We performed sequence analysis of the entire coding region and flanking splice sites of the SLC12A3 gene, revealing 303 mutations in 163 patients with a clinical suspicion of GS (Supplementary Screening for SLC12A3 deletions by MLPA To investigate the occurrence of deletions or duplications, multiplex ligation-dependent probe amplification (MLPA) analysis was performed for cases with a heterozygous mutation, and for cases with a homozygous mutation in which segregation in the family could not be confirmed. In these patients, we identified six heterozygous deletions, which affect at least part of the SLC12A3 coding region. Moreover, in patient 94, whom exons 5 and 6 could not be amplified by PCR analysis, a homozygous deletion of both exons was discovered. All deletions detected in this study are predicted to result in a frameshift and premature translational termination (Table 1; Supplementary  Table 1) . Taken together, we identified 114 different mutations, 31 of which have not been reported before. These novel variants include 3 deletions, 18 missense, 6 splice site and 4 nonsense mutations.
Wild-type and mutant NCC transport activity At present, SLC12A3 missense mutations have been shown to affect B220 of the in total 1030 NCC amino acids. Nevertheless, the functional consequence of most mutations has not been investigated. A total of seven identified NCC missense mutations, including five previously unidentified (Glu121Asp, Asn442Ser, Tyr489His, Pro751-Leu and Gln1030Arg) and two known variants (Ser475Cys and Thr392Ile) were selected to study their effect on NCC function. Thr392Ile was picked, as it appeared de novo together with the Asn442Ser variant in one patient. These NCC mutations affect amino acids, which are highly conserved among species (Figure 1a) . The localization of each examined mutant in the proposed topology of NCC is shown in Figure 1b . The Glu121Asp mutation is located within the N-terminus, which contains important phosphorylation residues (Thr46, Thr55 and Thr60). The Thr392Ile and Asn442Ser mutations are positioned in or in close proximity of the large extracellular loop, the Ser475Cys and Tyr489His are located in the fourth intracellular loop, and the Pro751Leu and Gln1030Arg mutations reside in the C-terminus. The Gln1030Arg mutation affects the last residue of NCC. This residue could be part of a protein-protein interaction motif, which could be important for cell membrane trafficking. The functionality of each mutant NCC transporter was investigated using the X. laevis oocyte heterologous expression system. To compare 22 Na + uptake between wild-type and each mutant NCC, all groups of oocytes were injected with 10 ng cRNA/oocyte. At the same day of the NCC-mediated 22 Na + uptake experiments, in parallel, microinjected X. laevis oocytes were selected to determine total membrane NCC protein expression using western blotting analysis. As shown in Figure 2a , total NCC expression was identical in all tested mutants. 22 Na + uptake by wild-type and mutant NCC-expressing oocytes was performed in the absence and presence of the thiazide diuretic, metalozone. In comparison with wild-type (100% ± 8%), the thiazide-sensitive 22 Na + uptake was significantly diminished for all mutants (Glu121Asp, 27±3%; Thr392Ile, 15±2%; Asn442Ser, 68 ± 6%; Ser475Cys, 40 ± 5%; Tyr489His, 48 ± 5%; Pro751Leu, 54 ± 4%; and Gln1030Arg, 58 ± 6%) (% relative to wild-type, n¼53-69 oocytes) (Figure 2b ). In the presence of thiazides, wildtype and mutant NCC-expressing oocytes showed equal levels of 22 Na + uptake as H 2 O-injected oocytes, demonstrating specific tracer uptakes for wild-type-and mutant-mediated NCC uptake (data no shown). Interestingly, the transport activity of the Thr392Ile mutant appeared to be totally abolished (similar levels of uptake for the Thr392Ile mutant in the absence and presence of thiazides or H 2 O-injected oocytes) (data no shown). Decreased transport activity, as observed for each NCC mutant, can result from impaired processing, disrupted membrane internalization or reduced function at the Functional analysis in Gitelman syndrome B Glaudemans et al cell membrane. To assess which of these processes are involved for each specific NCC mutant, the cell surface localization was examined.
Surface expression of wild-type and mutant NCC X. laevis oocytes were injected with H 2 O, and wild-type or mutant eGFP-NCC to study cell surface expression using confocal microscopy. 27 Figure 3a depicts representative images of X. laevis oocytes injected with H 2 O, and wild-type or mutant eGFP-NCC as stated, while Figure 3b presents the combined densitometric quantification of three independent experiments (B10 oocytes/experiment), in which the total fluorescence of wild-type eGFP-NCC was quantified and set at 100%. The total fluorescence of oocytes expressing wild-type eGFP-NCC proteins was significantly different from H 2 Oinjected oocytes (100 ± 9%, n¼44 versus 6 ± 1%, n¼62, respectively; Figure 3b ). In addition, the surface localization of NCC was significantly impaired for some of the mutants, namely Thr392Ile (38±5%), Asn442Ser (44 ± 5%) and Gln1030Arg (68 ± 7%) (n¼26-53; Figure 3b ). The plasma membrane localization of the NCC mutants Glu121Asp (104±13%), Ser475Cys (108±15%), Tyr489His (97 ± 10%) and Pro751Leu (110 ± 16%) was not affected (n¼22-44; Figure 3b ), which points toward an intrinsic defect in NCC function as the reason for the observed decreased transport activity.
DISCUSSION
GS is an autosomal recessive salt wasting disorder characterized by hypokalemic metabolic alkalosis, and secondary hypomagnesemia and hypocalciuria (OMIM 263800). The underlying cause for GS is loss-of-function mutations and deletions in the SLC12A3 gene. 23, 24, 28 In the present study, the DNA of 163 unrelated patients with a clinical suspicion of GS were selected to screen for mutation by sequence analysis of the complete SLC12A3 coding and flanking regions. In patients with a single heterozygous mutation and in patients with a homozygous mutation, we subsequently analyzed all exons for the occurrence of deletions using MLPA. Altogether, the GS phenotype was explained for 39 homozygous (24%) and 99 compound heterozygous (61%) patients. However, in 25 patients (15%), a mutation in only one of the alleles was identified (Supplementary Table 1 ). The pattern of inheritance for GS is autosomal recessive, which is confirmed by the fact that heterozygous relatives are clinically and metabolically asymptomatic. For that reason, it is likely that there was a failure to detect a mutation on the other allele in case of the heterozygous patients. Genetic alterations can be located in gene regions that were not analyzed, such as promoter sequence, 3¢ or 5¢ UTR, or intronic sequences.
It has been described that patients with mutations in the CLCNKB gene, associated with Bartter syndrome, can present with a Gitelmanlike phenotype. In a preliminary study, 77 patients with no mutations in the SLC12A3 gene were tested for mutations in the CLCNKB gene (data not shown). In only five cases pathogenic mutations in the CLCNKB gene have been identified, indicating that our failure to identify SLC12A3 mutations in this cohort of patients is probably due to misdiagnosis of the patients, and/or that these patients were sent in for exclusion of the diagnosis.
The SLC12A3 gene encodes the thiazide-sensitive NCC protein, which localizes to the luminal membrane of the DCT in the kidney. In these epithelial cells, NCC mediates the reabsorption of Na + and Cl À from the pro-urine to the intracellular compartment. As previously shown for Na + transporters such as NKCC2 and NCC, there are at least five potential mechanisms (class 1-5) by which mutations can reduce or abolish the activity of the transporter. 16 Class 1 mutants exhibit decreased protein stability leading to a complete absence of the transporter due to improperly processed or unstable mRNA. This often results from promoter alterations, splice site mutations, premature stop codons or deletions. In the present study, we identified nine splice site mutations, four nonsense mutations and seven deletions (Supplementary Table 1; Table 1 ), which may result in abnormal splicing of the mRNA transcript, insertion of a premature termination codon or frame shift in the transcript, leading to a truncated mutant mRNA transcript, and therefore low levels of NCC protein expression. 29 The effect of the c.(?_-6)_852+? and c.-66_23del deletions are unclear, as the start codon is within the deletion. For the c.-66_23del deletion it can be expected that either no protein is produced or that the translation initiation site has been moved downstream to Met53. The deletion of exons 1-6 (c.(?_-6)_852+?) probably disrupts protein production. The four intragenic deletions (exons 4-6, 5-6, 18 and 24) and the nine identified splice site mutations are predicted to lead to a frameshift and premature stopcodon. Owing to this premature termination (which also holds true for the four newly identified nonsense mutations), nonsense-mediated decay of the RNA is predicted and therefore probably no protein will be produced on these mutant alleles. The terminal deletion of exon 26 does not lead to nonsense-mediated decay, but probably will mimic missense mutations in the C-terminal part of the protein.
Additionally, we discovered 18 novel SLC12A3 missense mutations, which lead to amino-acid substitutions with an unknown effect on NCC function. We only included these mutations as pathogenic in case in silico analyses, together with other corroborating evidence, indicated that they could be classified as UV3 (probably pathogenic) or UV4 (pathogenic) according to the guidelines of the British and Functional analysis in Gitelman syndrome B Glaudemans et al Dutch clinical molecular biology societies. In all, five novel missense mutations and two previously described missense mutations 30 were selected and introduced into NCC to study their effect on protein stability, cellular localization and uptake activity by use of the X. laevis oocyte as an established heterologous expression system (Figure 1) . None of the mutations that were functionally characterized and presented in our manuscript have been identified in healthy controls or in SNP databases. In addition, the Glu121Asp, Thr392Ile and Asn442Ser mutations have been detected at least twice in non-related individuals in our patient group with clinical suspicion of GS.
Mutations in class 2 do not affect protein translation, but impair protein processing. As a result of misfolding, the NCC protein is retained in the ER and consequently targeted for degradation. Several studies have shown examples of class 2 NCC mutants. [12] [13] [14] In our study, we identified one mutant with class 2 NCC mutant characteristics. The Thr392Ile mutation displayed severely reduced Na + uptake, which was identical to background (data not shown). Furthermore, the amount of Thr392Ile NCC mutant on the plasma membrane was severely decreased. Previously, Hoover et al 27 showed that proper N-linked glycosylation of both residues (N404 and N424) in NCC is required for sufficient processing. The Thr392Ile mutation is situated in close proximity of these sites and may therefore hamper glycosylation. Interestingly, the upper band, which represents glycosylated NCC, seems to be (completely) absent for the Thr392Ile mutation on the western blot (Figure 1b) . So, impaired glycosylation of the Thr392Ile mutant likely obstructs processing to the plasma membrane, and consequently diminishes the NCC transport activity.
Class 3 mutants disrupt insertion of an otherwise functional protein into the plasma membrane. These mutations are characterized by a reduced Na + uptake, and cytoplasm/ER and plasma membrane localization. Most previously identified NCC mutants belong to class 3 [12] [13] [14] and examples in our study are Asn442Ser and Gln1030Arg (Table 2) . Presumably, these mutations produce NCC proteins of which the plasma membrane trafficking or internalization is affected. Interestingly, the Gln1030Arg mutation changes the last amino acid of NCC. Possibly, the Gln1030 amino acid is part of a protein-protein interaction motif, which is essential for trafficking.
Most of the mutations in our study belong to class 4. The Glu121Asp, Ser475Cys, Tyr489His and Pro751Leu mutations did reach the plasma membrane; however, their Na + uptake rate was significantly reduced in comparison with wild-type NCC (Table 2) . Notably, mutants Glu121Asp and Pro751Leu are situated within the N-and C-terminus of the protein (Figure 1b) , suggesting a role in activation or regulation. The Ser475Cys and Tyr489His mutants are positioned in or nearby the large extracellular loop, which may indicate a role for these amino acids in ion affinity. None of the studied mutants meet the criteria of a class 5 mutation in which protein removal or degradation is accelerated.
Interestingly, substances that assist protein folding (chemical chaperones) have been successfully used to restore the trafficking and function of mutant proteins in case of the vasopressin type 2 receptor and cystic fibrosis transmembrane conductance regulator. 31, 32 It would be interesting to investigate chaperone-induced trafficking of mutant NCC proteins (Table 2) , to ultimately use these chaperones as potential therapeutic agents. Altogether, this data contribute to the further understanding of the function and regulation of NCC. Future studies are needed to evaluate phenotype-genotype correlations to ultimately be able to predict, prevent or treat GS. Abbreviations: GS, Gitelman syndrome; NCC, NaCl cotransporter. The NCC mutant class (1-5) was determined by measuring NA + uptake capacity (Figure 2 ) and cell surface localization ( Figure 3) in Xenopus laevis oocytes, expressing wild-type or one of the seven selected NCC mutants (Table 1) . Class (1) decreased protein stability; class (2) impaired protein processing; class (3) disrupted insertion of an otherwise functional protein into plasma membrane; class (4) impaired functional properties of the cotransporter at the cell membrane; and class (5) accelerated protein removal or degradation. # indicates significant difference (Po0.05) in relation to wild-type NCC-injected oocytes.
